Factors and outcomes associated with adherence to statins among patients with newly diagnosed cardiovascular disease

Jiang Li1, Satish Mudiganti2, Hannah Husby2

  • 1Sutter Health Center for Health Systems Research-West/Palo Alto Medical Foundation Research Institute, 795 El Camino Real, Ames Building, Palo Alto, CA 94301, USA.

Insights

Statin adherence is influenced by insurance, race, and online portal use, with cardiologist visits improving outcomes. Tailored interventions can address disparities and enhance cardiovascular disease management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Statins effectively lower LDL-C and reduce cardiovascular events in patients with established cardiovascular disease (CVD).
  • Understanding factors influencing statin adherence is crucial for optimizing patient outcomes.
  • Electronic health records (EHR) and medication dispensed data offer insights into medication adherence patterns.

Purpose of the Study:

  • To examine factors associated with statin prescription filling and adherence.
  • To assess the impact of statin adherence on low-density lipoprotein cholesterol (LDL-C) control.
  • To identify demographic and healthcare system predictors of statin adherence in a large patient cohort.

Main Methods:

  • Secondary data analysis of longitudinal medication dispensed and EHR data (2010-2021) from a large health system.
  • Inclusion criteria: primary care patients aged 35+ with first CVD diagnosis and new statin prescriptions.
  • Multivariable logistic regression and survival analysis were used to identify predictors and assess outcomes.

Main Results:

  • 68.9% of 5155 patients were adherent to statins (Proportion of Days Covered ≥80%).
  • Predictors of adherence included insurance type, online patient portal use, race, age, statin intensity, and cardiologist visits.
  • Disparities in adherence were observed based on insurance type and race (NHB vs. NHW).
  • Cardiologist visits and high-intensity statins were associated with better adherence and LDL-C control.

Conclusions:

  • Demographic and healthcare system factors significantly influence statin adherence and LDL-C control.
  • Tailored interventions are needed to address disparities related to insurance, race, and technology access.
  • Integrating cardiologists into medication management can improve adherence and clinical outcomes for cardiovascular patients.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
884
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
119
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
39
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
67